PubMed Health⌕ Search

PubMed · 6804554

Intravenous nitroglycerin perfusion techniques--clinical implications.

Abstract

Two types of intravenous nitroglycerin (NTG) perfusion sets were studied using laboratory techniques. A known concentration of NTG was placed in each of these sets, and an evaluation was made as to the dose of NTG actually received by the patient after passage of the NTG solution through the sets. Set number one consisted of a glass container and polyvinyl chloride (PVC) tubing. After passage through this set, there was a rapid and significant decrease in the NTG concentration, i.e. the dose actually received by the patient is less than the dose theoretically administered. Set number two consisted of a polypropylene syringe and polyethylene tubing. After passage through this set, there was no significant change in the NTG concentration, i.e. the patient receives the full theoretical dose.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Hans, P Paris, F Mathot. 1982. Intravenous nitroglycerin perfusion techniques--clinical implications.. https://doi.org/10.1007/bf01694874

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗